Secretome versus PRP injections to improve hair density in androgenetic alopecia
Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital
This will try secretome injections versus platelet-rich plasma (PRP) injections to see which more effectively increases hair density and the terminal-to-vellus hair ratio in adults with androgenetic alopecia.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 25 Years to 59 Years |
| Sex | All |
| Sponsor | PT. Prodia Stem Cell Indonesia Industry-sponsored |
| Locations | 1 site (Denpasar, Bali) |
| Trial ID | NCT07429253 on ClinicalTrials.gov |
What this trial studies
This is a randomized, controlled, interventional Phase 1–2 trial comparing intradermal secretome injections with intradermal platelet-rich plasma (PRP) injections for androgenetic alopecia. Adults aged 25–59 with male pattern (Hamilton-Norwood II–VI) or female pattern (Ludwig I–III) hair loss are randomized to one of the two injection arms. Hair density and the terminal-to-vellus hair ratio are measured by trichoscopy/dermoscopy before and after a series of treatments to quantify changes. The trial is conducted at Prof. dr. I.G.N.G. Ngoerah Central General Hospital in Denpasar, Bali with safety monitoring appropriate for early-phase interventions.
Who should consider this trial
Good fit: Adults aged 25–59 with clinical androgenetic alopecia (men: Hamilton-Norwood II–VI; women: Ludwig I–III), not pregnant or breastfeeding, off anti-androgen agents and minoxidil for at least one month, without known allergies to treatment components, and willing to provide informed consent in Indonesian are ideal candidates.
Not a fit: Patients outside the age or pattern criteria, those with non-androgenetic hair loss, pregnant or breastfeeding women, people currently using anti-androgen or minoxidil therapies, or those with allergies to study materials are unlikely to receive benefit from this protocol.
Why it matters
Potential benefit: If successful, the treatment could provide a more effective injection-based option to increase hair density and favor growth of thicker terminal hairs for people with androgenetic alopecia.
How similar studies have performed: PRP injections have produced modest improvements in hair density in several prior trials, whereas secretome (stem-cell–derived) injections are a newer approach with promising pilot data but limited randomized evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients who are not currently pregnant or breastfeeding. * Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure. * Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * Patients who are proficient in Indonesian and willing to provide written informed consent. Exclusion Criteria: * Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent. * Patients presenting with types of hair loss other than androgenetic alopecia. * Patients currently undergoing therapy with 5-alpha reductase inhibitors. * Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study. * Patients with active infections and/or active dermatitis on the scalp. * Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * History of hypertrophic scarring or blood clotting (coagulation) disorders. * Patients unable to complete the research procedures in their entirety.
Where this trial is running
Denpasar, Bali
- Prof. dr. I.G.N.G. Ngoerah Central General Hospital — Denpasar, Bali, Indonesia (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.